Propofol formulations with non-reactive container closures

A sterile pharmaceutical composition of propofol in a container, comprising:

• a container which includes a closure and an oil-in-water emulsion for parenteral administration of propofol in the container,
• the emulsion comprising an oil phase comprising propofol and a solvent for propofol, and an aqueous phase comprising water for injection,
• the emulsion comprising from about 0 to about 10% by weight of the solvent,
• the emulsion further comprising a stabilizing layer for the oil phase, the stabilizing layer comprising a surfactant and a protein;
• where when the emulsion in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the emulsion maintains a propofol concentration (w/v) measured by HPLC that is at least 93% of the starting concentration (w/v) of the propofol;
• where the closure is selected from the group consisting of siliconized bromobutyl rubber, metal, and siliconized chlorobutyl rubber.

A sterile, injectable pharmaceutical composition in a container, comprising:

• a container which includes a closure and a composition in the container, the composition comprising
• a) microdroplets having a mean size of from about 20 nanometers to about 1000 nanometers, the microdroplets comprising a sphere of propofol surrounded by a stabilizing layer comprising a phospholipid and devoid of oils capable of supporting bacterial growth;
• and
• b) a pharmaceutically acceptable injectable carrier;
• where when the composition in the container sealed with the closure is agitated at a frequency of 300-400 cycles/minute for 16 hours at room temperature, the composition maintains a propofol concentration (w/v) measured by HPLC that is at least 93% of the starting concentration (w/v) of the propofol;
• where the closure is selected from the group consisting of siliconized bromobutyl rubber, metal, and siliconized chlorobutyl rubber.